Interestingly, the CTLA-4 ligands CD80 and CD86 as well as the PD-1 ligand PD-L1 had no impact on the patient’s outcome, while PD-L2 expression was not detectable in the AML patients (Supplemental Fig. S10). The gene discussed is CD86; the disease is acute myeloid leukemia.